Gilead Sciences' already dominant position in HIV pre-exposure prophylaxis (PrEP) could be extended if the FDA approves a new twice-yearly product later this year. The US regulator has started a ...
How can the UK accelerate medical innovation at a time when health systems are under strain and investment is slipping away? That question dominated conversations at the recent PharmaTech Integrates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results